Mi Kaihong, Kalady Matthew F, Quintini Cristiano, Khorana Alok A
Taussig Cancer Institute, Department of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Taussig Cancer Institute, Department of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA; Digestive Disease Institute, Department of Colorectal Surgery, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Surg Oncol Clin N Am. 2015 Jan;24(1):199-214. doi: 10.1016/j.soc.2014.09.006. Epub 2014 Oct 7.
Multiple new treatment options for metastatic colorectal cancer have been developed over the past 2 decades, including conventional chemotherapy and agents directed against vascular endothelial growth factor and epidermal growth factor receptor. Combination regimens, integrated with surgical approaches, have led to an increase in median survival, and a minority of patients with resectable disease can survive for years. Clinical decision-making therefore requires a strategic, biomarker-based multidisciplinary approach to maximize life expectancy and quality of life. This review describes systemic approaches to the treatment of patients with metastatic colorectal cancer, including integration with liver resection, other liver-directed therapies, and primary resection.
在过去20年里，已经开发出多种用于治疗转移性结直肠癌的新治疗方案，包括传统化疗以及针对血管内皮生长因子和表皮生长因子受体的药物。与手术方法相结合的联合治疗方案已使中位生存期延长，少数可切除疾病患者能够存活数年。因此，临床决策需要一种基于生物标志物的战略性多学科方法，以最大限度地提高预期寿命和生活质量。本综述描述了治疗转移性结直肠癌患者的全身治疗方法，包括与肝切除术、其他肝脏定向治疗和原发灶切除术相结合。
